Less than one quarter of pathology labs have adopted whole-slide imaging so far, but pathologists and companies in the space are optimistic of continued growth.
The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.
The tool uses two blood-based biomarkers and up to five clinical features to generate a risk score for prostate cancer aggressiveness.
The change applies to qualitative and quantitative hepatitis B virus antigen, antibody, and nucleic acid assays that are used to detect acute and chronic infections.
The agreement includes $650 million of 4.35 percent senior notes, $500 million of 4.55 percent senior notes, and $850 million of 4.8 percent senior notes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback